E Fund Management Co., Ltd. Lyell Immunopharma, Inc. Transaction History

E Fund Management Co., Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.45 - $3.35 $6,290 - $14,532	4,338 Added 24.8%	21,829 $32,000
Q2 2023 Aug 11, 2023	SELL	$1.89 - $3.86 $21,256 - $43,413	-11,247 Reduced 39.14%	17,491 $56,000
Q1 2023 May 11, 2023	SELL	$1.97 - $3.58 $2,834 - $5,151	-1,439 Reduced 4.77%	28,738 $68,000
Q4 2022 Feb 14, 2023	BUY	$2.78 - $8.09 $44,441 - $129,326	15,986 Added 112.65%	30,177 $105,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $78,618 - $117,359	14,191 New	14,191 $104,000

120

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $146M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.